Inside the research
Enovis Corporation
ENOV Research profile · latest available data
Price overview
$18.46
▲ +0.19 (+1.0%)
| 52w hi | $32.87 |
|---|---|
| 52w lo | $17.80 |
| Vol | 1.06M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.36
| Short | -0.30 |
|---|---|
| Medium | -0.31 |
| Long | -0.60 |
computed 2026-09-27
Key fundamentals
Enovis Corporation
Healthcare · Medical Devices
| Market cap | $1.06B |
|---|---|
| Enterprise value | $2.42B |
| Forward P/E | 5.00x |
| EV / EBITDA | 6.38x |
| P / S (ttm) | 0.46x |
| Profit margin | -48.0% |
| Return on equity | -54.1% |
| Revenue growth | +3.2% |
| Debt / equity | 92.56 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.06 | |
| Sector | +0.08 | |
| Technical | -0.26 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
Risk Metrics
| Beta vs SPX | 1.41 |
|---|---|
| Corr SPX | 0.41 |
| Annual vol | 55.3% |
| Annual ret | -27.7% |
| Sharpe | -0.50 |
| Max DD | -63.9% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-05-19 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2026-01-12 | Reg FD Disclosure, Exhibits | read |
| 2025-12-15 | Officer / Director Change | read |
| 2025-12-10 | Material Agreement, Material Obligation… | read |
| 2025-11-14 | Officer / Director Change | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-05-21 | Shareholder Vote | read |
| 2025-05-08 | Earnings Release, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.0% |
| HHI | 3,608 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Capital Research / Capital World | $58.48M | 2.82M |
| Millennium Management | $16.63M | 803.32K |
| AQR Capital Management | $12.23M | 590.65K |
| State Street Corp | $10.96M | 11.28M |
| Fidelity / FMR LLC | $4.75M | 4.95M |
| Bridgewater Associates | $1.60M | 77.09K |
| Citadel Advisors | $525.78K | 25.40K |
| T. Rowe Price Group | $1.64K | 79.42K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 14 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.25B | +11.8% | |
| Gross profit | $990.78M | +11.5% | |
| Operating income | -$775.72M | +29.0% | |
| Net income | -$33.26M | +28.2% | |
| Cash from ops | $217.29M | +12.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $18.31 | $18.79 | $18.06 | $18.46 | 1.06M |
| Sep 24 | $18.32 | $18.50 | $17.68 | $18.27 | 1.72M |
| Sep 23 | $18.29 | $18.56 | $17.86 | $18.24 | 1.18M |
| Sep 22 | $18.45 | $18.65 | $18.13 | $18.39 | 1.79M |
| Sep 21 | $18.18 | $18.18 | $17.48 | $18.04 | 2.59M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →